A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
Open Access
- 1 April 2012
- journal article
- research article
- Published by Taylor & Francis Ltd in Drug Design, Development and Therapy
- Vol. 6, 71-9
- https://doi.org/10.2147/DDDT.S29125
Abstract
Peer reviewed article authored by (Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M). Read article or submit your manuscript for publishing.Keywords
This publication has 12 references indexed in Scilit:
- A 12-Month Phase 3 Study of Pasireotide in Cushing's DiseaseNew England Journal of Medicine, 2012
- Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II TrialJournal of Clinical Endocrinology & Metabolism, 2010
- Somatostatin analog octreotide LAR®in gastro–entero–pancreatic tumorsExpert Review of Anticancer Therapy, 2009
- Pasireotide (SOM230): Development, mechanism of action and potential applicationsMolecular and Cellular Endocrinology, 2008
- Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001)Annales d'Endocrinologie, 2008
- Lanreotide Autogel??Drugs, 2008
- Rationale for the use of somatostatin analogs as antitumor agentsAnnals of Oncology, 2006
- A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic PatientsJournal of Clinical Endocrinology & Metabolism, 2004
- A Novel Somatostatin Mimic with Broad Somatotropin Release Inhibitory Factor Receptor Binding and Superior Therapeutic PotentialJournal of Medicinal Chemistry, 2003
- SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profileActa Endocrinologica, 2002